Repros Announces Acceptance of Dossier for Enclomiphene for Secondary Hypogonadism by European Authorities
October 05, 2016 10:35 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, Oct. 05, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that it has received confirmation of acceptance of its September 12, 2016 filing for...
FDA Schedules Advisory Committee Meeting To Discuss Secondary Hypogonadism
September 26, 2016 09:15 ET
|
Repros Therapeutics Inc.
Repros Therapeutics to participate as a Sponsor -- developing a therapy specifically designed to treat secondary hypogonadism THE WOODLANDS, Texas, Sept. 26, 2016 (GLOBE NEWSWIRE) -- Repros...
Repros Announces Submission of MAA to the European Medicines Agency for Enclomiphene in the Treatment of Secondary Hypogonadism
September 12, 2016 11:45 ET
|
Repros Therapeutics Inc.
UK designated as rapporteur and France as co-rapporteurAverage time to approval 13 – 16 months THE WOODLANDS, Texas, Sept. 12, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX)...
Repros Provides Phase 2 Results Showing Positive Outcomes for Oral Proellex® in Women With Moderate to Severe Endometriosis
September 07, 2016 16:01 ET
|
Repros Therapeutics Inc.
Subjects with moderate to severe endometriosis experienced relief of menstrual pain and a reduction in the use of pain medication with the use of Proellex® Proellex® subjects’ menstrual pain by BBSS...
Repros Provides Six Month Interim Results for Enclomiphene Study in Obese Secondary Hypogonadal Men
August 15, 2016 16:01 ET
|
Repros Therapeutics Inc.
Six month interim assessment of testosterone (T) levels shows statistically and clinically significant increases in total T (p = 0.0017) and free T (p = 0.0020) superior to placeboEffects of diet...
Repros Therapeutics Inc.® Reports Second Quarter 2016 Financial Results
August 09, 2016 09:15 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, Aug. 09, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the second quarter ended June 30, 2016. Financial Results ...
Repros Provides Update on EU Submission of Enclomiphene for the Treatment of Secondary Hypogonadism and 3 Month Interim Results for Enclomiphene Study in Obese Secondary Hypogonadal Men
June 01, 2016 16:01 ET
|
Repros Therapeutics Inc.
EU submission on track with anticipated registration decision expected Fall 2017 UK designated as rapporteur and France as co-rapporteur for the centralized review of the enclomiphene marketing...
Repros Reports Positive Clinical Data for Oral Proellex® in Women With Severe Menstrual Bleeding Due to Uterine Fibroids
May 18, 2016 16:01 ET
|
Repros Therapeutics Inc.
Primary endpoint of induction of amenorrhea met for the pooled oral doses compared to placebo, p=0.0004Proellex®-treated subjects reported a median 100% (mean 95%) reduction in diary reports of...
Repros Announces the Appointment of Mr. Patrick Fourteau as Chairman of the Board
May 16, 2016 16:00 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, May 16, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that it has appointed Mr. Patrick Fourteau to its Board of Directors, where he will...
Repros Therapeutics Inc.® Reports First Quarter 2016 Financial Results
May 10, 2016 09:15 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, May 10, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the first quarter ended March 31, 2016. Financial Results ...